CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Cost Effectiveness and Future of CAR T Therapy

January 9th 2018

Evaluating CAR T-Cell Therapy Use

January 9th 2018

Potential for CAR T-Cell Therapy for R/R AML

January 9th 2018

BCMA-Targeted CAR T-Cell Therapy for Myeloma

January 9th 2018

Allogeneic CAR T-Cell Approaches for NHL

January 9th 2018

The Use of CTL019 in Lymphoma

January 9th 2018

JCAR017 for B-Cell NHL

January 9th 2018

Axi-Cel and Future of CAR T-Cell Therapy in Lymphoma

January 9th 2018

Clinical Data for Axi-Cel in Lymphoma

January 9th 2018

FDA Approval for Axi-Cel in NHL

January 9th 2018

Need for Salvage Therapies in R/R NHL

January 9th 2018

Clinical Data Behind CAR T-Cell Therapies in ALL

January 9th 2018

Tisagenlecleucel for Relapsed/Refractory ALL

January 9th 2018

The Promise of CAR T-Cell Therapy for ALL

January 9th 2018

Mechanisms of Resistance for CAR T Therapy

January 9th 2018

Managing CAR T-Cell Therapy Toxicity

January 9th 2018

Practicality of CAR T Therapy

January 9th 2018

The Status of CAR T in Hematologic Malignancies

January 9th 2018

Dr. Brentjens on Research Beyond CD19 in CAR T-Cell Therapy

January 5th 2018

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for CAR T-cell therapy.

Dr. Berdeja Discusses Study of bb2121 Anti-BCMA CAR-T Cell Therapy

January 3rd 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses a study of bb2121, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy.